Header Logo

Connection

NICOLA HANANIA to Middle Aged

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Middle Aged.
NICOLA HANANIA
Connection Strength
1.565
Middle Aged
  1. The impact of age on prevalence of anxiety, depression and stress in patients with chronic obstructive pulmonary disease. J Psychosom Res. 2026 Jan; 200:112472.
    View in: PubMed
    Score: 0.057
  2. Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep; 245:108172.
    View in: PubMed
    Score: 0.055
  3. Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
    View in: PubMed
    Score: 0.051
  4. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.043
  5. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.036
  6. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.035
  7. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.035
  8. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.033
  9. Factors associated with depressive symptoms in uncontrolled asthmatics. J Asthma. 2018 05; 55(5):555-560.
    View in: PubMed
    Score: 0.032
  10. Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. J Altern Complement Med. 2017 Sep; 23(9):696-704.
    View in: PubMed
    Score: 0.032
  11. Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. Ann Am Thorac Soc. 2017 May; 14(5):659-666.
    View in: PubMed
    Score: 0.032
  12. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.031
  13. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.030
  14. The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
    View in: PubMed
    Score: 0.029
  15. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.028
  16. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014 Feb; 108(2):366-75.
    View in: PubMed
    Score: 0.025
  17. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.024
  18. Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. Mayo Clin Proc. 2012 Sep; 87(9):862-70.
    View in: PubMed
    Score: 0.023
  19. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.023
  20. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
    View in: PubMed
    Score: 0.022
  21. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011 Oct; 105(10):1516-22.
    View in: PubMed
    Score: 0.021
  22. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011 Aug; 8(4):293-9.
    View in: PubMed
    Score: 0.021
  23. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.021
  24. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
    View in: PubMed
    Score: 0.020
  25. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
    View in: PubMed
    Score: 0.020
  26. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):604-11.
    View in: PubMed
    Score: 0.020
  27. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010 May 06; 5:125-32.
    View in: PubMed
    Score: 0.019
  28. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010 Aug; 104(8):1160-70.
    View in: PubMed
    Score: 0.019
  29. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
    View in: PubMed
    Score: 0.019
  30. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.018
  31. Evaluation of obstructive lung disease with vibration response imaging. J Asthma. 2008 Dec; 45(10):923-30.
    View in: PubMed
    Score: 0.018
  32. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008; 21(1):134-41.
    View in: PubMed
    Score: 0.016
  33. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
    View in: PubMed
    Score: 0.015
  34. Effect of a self-directed lifestyle-based weight management program among patients with comorbid COPD and sleep apnea: a secondary analysis of the INSIGHT COPD trial. Ann Am Thorac Soc. 2026 Mar 01; 23(3):419-428.
    View in: PubMed
    Score: 0.015
  35. Hyperglycemia, receptor for advanced glycation end products, and small airways dysfunction in asthma. Ann Allergy Asthma Immunol. 2026 Feb; 136(2):173-179.e3.
    View in: PubMed
    Score: 0.014
  36. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
    View in: PubMed
    Score: 0.014
  37. Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort. Aging (Albany NY). 2025 Jul 03; 17(7):1590-1623.
    View in: PubMed
    Score: 0.014
  38. A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA. 2025 06 24; 333(24):2164-2175.
    View in: PubMed
    Score: 0.014
  39. Asthma outcomes in a safety net hospital system: A comparative study to a national cohort. Respir Med. 2025 Apr-May; 240:108032.
    View in: PubMed
    Score: 0.014
  40. Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 05; 241:108015.
    View in: PubMed
    Score: 0.014
  41. Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. Chest. 2025 Jul; 168(1):56-66.
    View in: PubMed
    Score: 0.014
  42. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
    View in: PubMed
    Score: 0.014
  43. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
    View in: PubMed
    Score: 0.013
  44. Association of Insulin Resistance With Radiographic Lung Abnormalities and Incident Lung Disease: The Framingham Offspring Study. Diabetes Care. 2025 Jan 01; 48(1):143-148.
    View in: PubMed
    Score: 0.013
  45. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025 01; 236:107846.
    View in: PubMed
    Score: 0.013
  46. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.013
  47. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
    View in: PubMed
    Score: 0.013
  48. Identification of sleep phenotypes in COPD using machine learning-based cluster analysis. Respir Med. 2024 06; 227:107641.
    View in: PubMed
    Score: 0.013
  49. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.013
  50. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.013
  51. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.012
  52. Use of the Spirometric "Fixed-Ratio" Underdiagnoses COPD in African-Americans in a Longitudinal Cohort Study. J Gen Intern Med. 2023 10; 38(13):2988-2997.
    View in: PubMed
    Score: 0.012
  53. Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
    View in: PubMed
    Score: 0.011
  54. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.010
  55. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
    View in: PubMed
    Score: 0.010
  56. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
    View in: PubMed
    Score: 0.010
  57. The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. Ann Am Thorac Soc. 2020 04; 17(4):450-456.
    View in: PubMed
    Score: 0.010
  58. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.010
  59. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
    View in: PubMed
    Score: 0.009
  60. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019 Jul - Aug; 154:86-92.
    View in: PubMed
    Score: 0.009
  61. Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. Chest. 2019 08; 156(2):228-238.
    View in: PubMed
    Score: 0.009
  62. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
    View in: PubMed
    Score: 0.009
  63. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848.
    View in: PubMed
    Score: 0.008
  64. Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839.
    View in: PubMed
    Score: 0.008
  65. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.008
  66. Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 01; 313(5):R620-R629.
    View in: PubMed
    Score: 0.008
  67. Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. Respir Med. 2017 Sep; 130:92-97.
    View in: PubMed
    Score: 0.008
  68. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
    View in: PubMed
    Score: 0.008
  69. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
    View in: PubMed
    Score: 0.008
  70. Factors associated with emergency department dependence of patients with asthma. Chest. 1997 Feb; 111(2):290-5.
    View in: PubMed
    Score: 0.008
  71. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
    View in: PubMed
    Score: 0.008
  72. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.008
  73. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
    View in: PubMed
    Score: 0.008
  74. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
    View in: PubMed
    Score: 0.007
  75. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.007
  76. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
    View in: PubMed
    Score: 0.007
  77. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016 Apr; 149(4):927-35.
    View in: PubMed
    Score: 0.007
  78. Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respir Med. 2016 Feb; 111:30-8.
    View in: PubMed
    Score: 0.007
  79. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995 Nov; 96(5 Pt 1):571-9.
    View in: PubMed
    Score: 0.007
  80. Health-care utilization after near-fatal asthma. Chest. 1995 Jun; 107(6):1564-9.
    View in: PubMed
    Score: 0.007
  81. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.007
  82. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.007
  83. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014 Sep; 108(9):1310-20.
    View in: PubMed
    Score: 0.006
  84. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.006
  85. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.006
  86. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.006
  87. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
    View in: PubMed
    Score: 0.006
  88. Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. J Hosp Med. 2013 Apr; 8(4):165-72.
    View in: PubMed
    Score: 0.006
  89. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol. 2013 Apr; 110(4):240-6, 246.e1.
    View in: PubMed
    Score: 0.006
  90. Racial differences in CT phenotypes in COPD. COPD. 2013 Feb; 10(1):20-7.
    View in: PubMed
    Score: 0.006
  91. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.006
  92. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD. 2012 Apr; 9(2):151-9.
    View in: PubMed
    Score: 0.006
  93. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol. 2012 May; 129(5):1252-1258.e1.
    View in: PubMed
    Score: 0.006
  94. Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J Appl Physiol (1985). 2012 Jan; 112(1):42-7.
    View in: PubMed
    Score: 0.005
  95. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011 Oct; 261(1):274-82.
    View in: PubMed
    Score: 0.005
  96. Racial differences in quality of life in patients with COPD. Chest. 2011 Nov; 140(5):1169-1176.
    View in: PubMed
    Score: 0.005
  97. Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism. 2011 Oct; 60(10):1449-55.
    View in: PubMed
    Score: 0.005
  98. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May; 86(5):375-81.
    View in: PubMed
    Score: 0.005
  99. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.005
  100. Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010 Feb 18; 5:1-10.
    View in: PubMed
    Score: 0.005
  101. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
    View in: PubMed
    Score: 0.005
  102. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J. 2009 Sep; 18(3):198-207.
    View in: PubMed
    Score: 0.005
  103. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
    View in: PubMed
    Score: 0.004
  104. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
    View in: PubMed
    Score: 0.004
  105. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
    View in: PubMed
    Score: 0.004
  106. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
    View in: PubMed
    Score: 0.004
  107. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.004
  108. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol. 2006 Dec; 118(6):1226-33.
    View in: PubMed
    Score: 0.004
  109. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
    View in: PubMed
    Score: 0.003
  110. The accuracy of a handheld portable spirometer. Chest. 1996 Jan; 109(1):152-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.